{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T03:31:13Z","timestamp":1794540673825,"version":"4.9.1"},"reference-count":143,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2015,11,1]],"date-time":"2015-11-01T00:00:00Z","timestamp":1446336000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","ijaaonline.com","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Antimicrobial Agents"],"published-print":{"date-parts":[[2015,11]]},"DOI":"10.1016\/j.ijantimicag.2015.08.011","type":"journal-article","created":{"date-parts":[[2015,9,26]],"date-time":"2015-09-26T00:48:16Z","timestamp":1443228496000},"page":"483-493","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":181,"title":["A resurgence of \u03b2-lactamase inhibitor combinations effective against multidrug-resistant Gram-negative pathogens"],"prefix":"10.1016","volume":"46","author":[{"given":"Karen","family":"Bush","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijantimicag.2015.08.011_bib0720","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1093\/oxfordjournals.bmb.a071942","article-title":"\u03b2-Lactamases","volume":"40","author":"Medeiros","year":"1984","journal-title":"Br Med Bull"},{"key":"10.1016\/j.ijantimicag.2015.08.011_bib0725","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/S0065-7743(08)60628-4","article-title":"Bacterial resistance to \u03b2-lactams: the \u03b2-lactamases","volume":"13","author":"Fisher","year":"1978","journal-title":"Annu Rep Med Chem"},{"key":"10.1016\/j.ijantimicag.2015.08.011_bib0730","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1128\/AAC.27.3.393","article-title":"Role of \u03b2-lactam hydrolysis in the mechanism of resistance of a \u03b2-lactamase-constitutive Enterobacter cloacae strain to expanded-spectrum \u03b2-lactams","volume":"27","author":"Vu","year":"1985","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2015.08.011_bib0735","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1128\/AAC.27.4.555","article-title":"Resistance caused by decreased penetration of \u03b2-lactam antibiotics into Enterobacter cloacae","volume":"27","author":"Bush","year":"1985","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2015.08.011_bib0740","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1038\/nature10388","article-title":"Antibiotic resistance is ancient","volume":"477","author":"D\u2019Costa","year":"2011","journal-title":"Nature"},{"key":"10.1016\/j.ijantimicag.2015.08.011_bib0745","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1007\/s10156-013-0640-7","article-title":"The ABCD's of \u03b2-lactamase nomenclature","volume":"19","author":"Bush","year":"2013","journal-title":"J Infect Chemother"},{"key":"10.1016\/j.ijantimicag.2015.08.011_bib0750","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1098\/rstb.1980.0049","article-title":"The structure of \u03b2-lactamases","volume":"289","author":"Ambler","year":"1980","journal-title":"Philos Trans R Soc Lond Biol Sci"},{"key":"10.1016\/j.ijantimicag.2015.08.011_bib0755","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1128\/AAC.39.6.1211","article-title":"A functional classification scheme for \u03b2-lactamases and its correlation with molecular structure","volume":"39","author":"Bush","year":"1995","journal-title":"Antimicrob Agents Chemother"},{"issue":"Suppl. 1","key":"10.1016\/j.ijantimicag.2015.08.011_bib0760","doi-asserted-by":"crossref","first-page":"S19","DOI":"10.1093\/clinids\/24.Supplement_1.S19","article-title":"Evolution and dissemination of \u03b2-lactamases accelerated by generations of \u03b2-lactam antibiotics","volume":"24","author":"Medeiros","year":"1997","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2015.08.011_bib0765","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1016\/S0140-6736(76)92467-3","article-title":"Penicillinase-producing Neisseria gonorrhoeae","volume":"2","author":"Ashford","year":"1976","journal-title":"Lancet"},{"key":"10.1016\/j.ijantimicag.2015.08.011_bib0770","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1016\/S0140-6736(77)92891-4","article-title":"Evidence for two distinct types of penicillinase-producing Neisseria gonorrhoeae","volume":"2","author":"Perine","year":"1977","journal-title":"Lancet"},{"key":"10.1016\/j.ijantimicag.2015.08.011_bib0775","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1128\/AAC.13.4.618","article-title":"Contribution of a TEM-1-like \u03b2-lactamase to penicillin resistance in Neisseria gonorrhoeae","volume":"13","author":"Bergstr\u00f6m","year":"1978","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2015.08.011_bib0780","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1016\/S0140-6736(81)91214-9","article-title":"Ampicillin treatment failure of apparently beta-lactamase-negative Haemophilus influenzae type b meningitis due to novel beta-lactamase","volume":"ii","author":"Rubin","year":"1981","journal-title":"Lancet"},{"key":"10.1016\/j.ijantimicag.2015.08.011_bib0785","doi-asserted-by":"crossref","first-page":"668","DOI":"10.7164\/antibiotics.29.668","article-title":"Naturally-occurring \u03b2-lactamase inhibitors with antibacterial activity","volume":"29","author":"Brown","year":"1976","journal-title":"J Antibiot (Tokyo)"},{"key":"10.1016\/j.ijantimicag.2015.08.011_bib0790","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1128\/AAC.14.3.414","article-title":"CP-45.899, a \u03b2-lactamase inhibitor that extends the antibacterial spectrum of \u03b2-lactams: initial bacteriological characterization","volume":"14","author":"English","year":"1978","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2015.08.011_bib0795","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1128\/AAC.26.4.580","article-title":"Comparative activities of the \u03b2-lactamase inhibitors YTR 830, sodium clavulanate, and sulbactam combined with amoxicillin or ampicillin","volume":"26","author":"Aronoff","year":"1984","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2015.08.011_bib0800","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/j.ijantimicag.2011.12.012","article-title":"Fourteen years in resistance","volume":"39","author":"Livermore","year":"2012","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.ijantimicag.2015.08.011_bib0805","series-title":"Antibiotic resistance threats in the United States, 2013","author":"US Centers for Disease Control and Prevention","year":"2013"},{"key":"10.1016\/j.ijantimicag.2015.08.011_bib0810","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1016\/S1473-3099(14)70825-4","article-title":"UK and European Union public and charitable funding from 2008 to 2013 for bacteriology and antibiotic research in the UK: an observational study","volume":"14","author":"Bragginton","year":"2014","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.ijantimicag.2015.08.011_bib0815","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.coph.2014.09.008","article-title":"Discovery and development of new antibacterial agents targeting Gram-negative bacteria in the era of pandrug resistance: is the future promising?","volume":"18","author":"Page","year":"2014","journal-title":"Curr Opin Pharmacol"},{"key":"10.1016\/j.ijantimicag.2015.08.011_bib0820","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1111\/nyas.12023","article-title":"Proliferation and significance of clinically relevant \u03b2-lactamases","volume":"1277","author":"Bush","year":"2013","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/j.ijantimicag.2015.08.011_bib0825","doi-asserted-by":"crossref","first-page":"1846","DOI":"10.2174\/13895575113139990074","article-title":"\u03b2-Lactamase inhibitors: an update","volume":"13","author":"Chen","year":"2013","journal-title":"Mini Rev Med Chem"},{"key":"10.1016\/j.ijantimicag.2015.08.011_bib0830","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1128\/AAC.00826-13","article-title":"New \u03b2-lactamase inhibitors: a therapeutic renaissance in an MDR world","volume":"58","author":"Drawz","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2015.08.011_bib0835","doi-asserted-by":"crossref","first-page":"13","DOI":"10.2147\/CE.S40698","article-title":"Ceftazidime\u2013avibactam: an evidence-based review of its pharmacology and potential use in the treatment of Gram-negative bacterial infections","volume":"9","author":"Lagac\u00e9-Wiens","year":"2014","journal-title":"Core Evid"},{"key":"10.1016\/j.ijantimicag.2015.08.011_bib0840","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1177\/1060028014556652","article-title":"\u03b2-Lactam\/\u03b2-lactamase inhibitor combinations: from then to now","volume":"49","author":"Toussaint","year":"2015","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.ijantimicag.2015.08.011_bib0845","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1007\/s10096-015-2375-0","article-title":"New promising \u03b2-lactamase inhibitors for clinical use","volume":"34","author":"Olsen","year":"2015","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"10.1016\/j.ijantimicag.2015.08.011_bib0850","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1128\/AAC.11.5.852","article-title":"Clavulanic acid: a \u03b2-lactamase inhibitor from Streptomyces clavuligerus","volume":"11","author":"Reading","year":"1977","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2015.08.011_bib0855","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1128\/AAC.38.4.767","article-title":"Comparative activities of clavulanic acid, sulbactam, and tazobactam against clinically important \u03b2-lactamases","volume":"38","author":"Payne","year":"1994","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2015.08.011_bib0860","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1128\/AAC.13.3.389","article-title":"In vitro study of clavulanic acid in combination with penicillin, amoxycillin, and carbenicillin","volume":"13","author":"Wise","year":"1978","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2015.08.011_bib0865","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1093\/infdis\/167.2.448","article-title":"Effect of sulbactam on infections caused by imipenem-resistant Acinetobacter calcoaceticus biotype anitratus","volume":"167","author":"Urban","year":"1993","journal-title":"J Infect Dis"},{"key":"10.1016\/j.ijantimicag.2015.08.011_bib0870","doi-asserted-by":"crossref","first-page":"5480","DOI":"10.1021\/ol202195n","article-title":"A concise synthesis of a \u03b2-lactamase inhibitor","volume":"13","author":"Mangion","year":"2011","journal-title":"Org Lett"},{"key":"10.1016\/j.ijantimicag.2015.08.011_bib0875","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1093\/jac\/dkh358","article-title":"In vitro activity of AVE1330A, an innovative broad-spectrum non-\u03b2-lactam \u03b2-lactamase inhibitor","volume":"54","author":"Bonnefoy","year":"2004","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2015.08.011_bib0880","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1093\/jac\/dkp197","article-title":"In vitro activity of the \u03b2-lactamase inhibitor NXL104 against KPC-2 carbapenemase and Enterobacteriaceae expressing KPC carbapenemases","volume":"64","author":"Stachyra","year":"2009","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2015.08.011_bib0885","doi-asserted-by":"crossref","first-page":"5132","DOI":"10.1128\/AAC.00568-10","article-title":"Mechanistic studies of the inactivation of TEM-1 and P99 by NXL104, a novel non-\u03b2-lactam \u03b2-lactamase inhibitor","volume":"54","author":"Stachyra","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2015.08.011_bib0890","doi-asserted-by":"crossref","first-page":"11663","DOI":"10.1073\/pnas.1205073109","article-title":"Avibactam is a covalent, reversible, non-\u03b2-lactam \u03b2-lactamase inhibitor","volume":"109","author":"Ehmann","year":"2012","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.ijantimicag.2015.08.011_bib0895","doi-asserted-by":"crossref","first-page":"2496","DOI":"10.1128\/AAC.02247-12","article-title":"Structural insight into potent broad-spectrum inhibition with reversible recyclization mechanism: avibactam in complex with CTX-M-15 and Pseudomonas aeruginosa AmpC \u03b2-lactamases","volume":"57","author":"Lahiri","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2015.08.011_bib0900","doi-asserted-by":"crossref","first-page":"5704","DOI":"10.1128\/AAC.03057-14","article-title":"Avibactam and class C \u03b2-lactamases: mechanism of inhibition, conservation of the binding pocket, and implications for resistance","volume":"58","author":"Lahiri","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2015.08.011_bib0905","doi-asserted-by":"crossref","first-page":"5174","DOI":"10.1021\/bi500589x","article-title":"Inactivation of TEM-1 by avibactam (NXL-104): insights from quantum mechanics\/molecular mechanics metadynamics simulations","volume":"53","author":"Sgrignani","year":"2014","journal-title":"Biochemistry"},{"key":"10.1016\/j.ijantimicag.2015.08.011_bib0910","doi-asserted-by":"crossref","first-page":"27960","DOI":"10.1074\/jbc.M113.485979","article-title":"Kinetics of avibactam inhibition against class A, C, and D \u03b2-lactamases","volume":"288","author":"Ehmann","year":"2013","journal-title":"J Biol Chem"},{"key":"10.1016\/j.ijantimicag.2015.08.011_bib0915","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1021\/cb500703p","article-title":"Molecular basis of selective inhibition and slow reversibility of avibactam against class D carbapenemases: a structure-guided study of OXA-24 and OXA-48","volume":"10","author":"Lahiri","year":"2015","journal-title":"ACS Chem Biol"},{"key":"10.1016\/j.ijantimicag.2015.08.011_bib0920","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1016\/j.bmcl.2013.12.101","article-title":"Discovery of MK-7655, a \u03b2-lactamase inhibitor for combination with Primaxin\u00ae","volume":"24","author":"Blizzard","year":"2014","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1016\/j.ijantimicag.2015.08.011_bib0925","doi-asserted-by":"crossref","first-page":"2779","DOI":"10.1093\/jac\/dkv166","article-title":"OP0595, a new diazabicyclooctane: mode of action as a serine \u03b2-lactamase inhibitor, antibiotic and \u03b2-lactam \u2018enhancer\u2019","volume":"70","author":"Morinaka","year":"2015","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2015.08.011_bib0930","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1093\/oxfordjournals.jbchem.a130799","article-title":"Temperature-jump studies on benzeneboronic acid\u2013serine protease interactions. Subtilisin and \u03b1-chymotrypsin","volume":"77","author":"Nakatani","year":"1975","journal-title":"J Biochem"},{"key":"10.1016\/j.ijantimicag.2015.08.011_bib0935","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1042\/bj2210505","article-title":"Purification of \u03b2-lactamases by affinity chromatography on phenylboronic acid\u2013agarose","volume":"221","author":"Cartwright","year":"1984","journal-title":"Biochem J"},{"key":"10.1016\/j.ijantimicag.2015.08.011_bib0940","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1042\/bj2090229","article-title":"The inhibition of class C \u03b2-lactamases by boronic acids","volume":"209","author":"Beesley","year":"1983","journal-title":"Biochem J"},{"key":"10.1016\/j.ijantimicag.2015.08.011_bib0945","doi-asserted-by":"crossref","first-page":"2330","DOI":"10.1110\/ps.8.11.2330","article-title":"The complexed structure and antimicrobial activity of a non-\u03b2-lactam inhibitor of AmpC \u03b2-lactamase","volume":"8","author":"Powers","year":"1999","journal-title":"Protein Sci"},{"key":"10.1016\/j.ijantimicag.2015.08.011_bib0950","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1021\/ja0288338","article-title":"Nanomolar inhibitors of AmpC \u03b2-lactamase","volume":"125","author":"Morandi","year":"2003","journal-title":"J Am Chem Soc"},{"key":"10.1016\/j.ijantimicag.2015.08.011_bib0955","doi-asserted-by":"crossref","first-page":"3682","DOI":"10.1021\/acs.jmedchem.5b00127","article-title":"Discovery of a cyclic boronic acid \u03b2-lactamase inhibitor (RPX7009) with utility vs class A serine carbapenemases","volume":"58","author":"Hecker","year":"2015","journal-title":"J Med Chem"},{"key":"10.1016\/j.ijantimicag.2015.08.011_bib0960","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1038\/ja.2010.20","article-title":"Inhibition of metallo-\u03b2-lactamases by pyridine monothiocarboxylic acid analogs","volume":"63","author":"Roll","year":"2010","journal-title":"J Antibiot (Tokyo)"},{"key":"10.1016\/j.ijantimicag.2015.08.011_bib0965","doi-asserted-by":"crossref","first-page":"3625","DOI":"10.1128\/AAC.01397-09","article-title":"In vitro potentiation of carbapenems with ME1071, a novel metallo-\u03b2-lactamase inhibitor, against metallo-\u03b2-lactamase-producing Pseudomonas aeruginosa clinical isolates","volume":"54","author":"Ishii","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2015.08.011_bib0970","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1093\/jac\/dks350","article-title":"Activity of carbapenems with ME1071 (disodium 2,3-diethylmaleate) against Enterobacteriaceae and Acinetobacter spp. with carbapenemases, including NDM enzymes","volume":"68","author":"Livermore","year":"2013","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2015.08.011_bib0975","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/j.ijantimicag.2013.05.016","article-title":"In vivo efficacy of biapenem with ME1071, a novel metallo-\u03b2-lactamase (MBL) inhibitor, in a murine model mimicking ventilator-associated pneumonia caused by MBL-producing Pseudomonas aeruginosa","volume":"42","author":"Yamada","year":"2013","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.ijantimicag.2015.08.011_bib0980","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1038\/nature13445","article-title":"Aspergillomarasmine A overcomes metallo-\u03b2-lactamase antibiotic resistance","volume":"510","author":"King","year":"2014","journal-title":"Nature"},{"key":"10.1016\/j.ijantimicag.2015.08.011_bib0985","first-page":"2693","article-title":"Novel microbial inhibitors of angiotensin-converting enzyme, aspergillomarasmines A and 8","volume":"47","author":"Mikami","year":"1983","journal-title":"Agric Biol Chem"},{"key":"10.1016\/j.ijantimicag.2015.08.011_bib0990","first-page":"565","article-title":"Evaluation of enzyme inhibition data in screening for new drugs","volume":"12","author":"Bush","year":"1986","journal-title":"Drugs Exp Clin Res"},{"key":"10.1016\/j.ijantimicag.2015.08.011_bib0995","doi-asserted-by":"crossref","first-page":"13329","DOI":"10.1016\/S0021-9258(18)98843-5","article-title":"Toxin production in Pyrenophora teres, the ascomycete causing the net-spot blotch disease of barley (Hordeum vulgare L.)","volume":"266","author":"Friis","year":"1991","journal-title":"J Biol Chem"},{"key":"10.1016\/j.ijantimicag.2015.08.011_bib1000","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1254\/jjp.63.187","article-title":"Pharmacological profiles of aspergillomarasmines as endothelin converting enzyme inhibitors","volume":"63","author":"Matsuura","year":"1993","journal-title":"Jpn J Pharmacol"},{"key":"10.1016\/j.ijantimicag.2015.08.011_bib1005","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1093\/jac\/dku538","article-title":"NOTA: a potent metallo-\u03b2-lactamase inhibitor","volume":"5","author":"Somboro","year":"2015","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2015.08.011_bib1010","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1128\/AAC.00860-06","article-title":"In vitro and in vivo activities of a new cephalosporin, FR264205, against Pseudomonas aeruginosa","volume":"51","author":"Takeda","year":"2007","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2015.08.011_bib1015","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1128\/AAC.00834-09","article-title":"Activity of a new antipseudomonal cephalosporin, CXA-101 (FR264205), against carbapenem-resistant and multidrug-resistant Pseudomonas aeruginosa clinical strains","volume":"54","author":"Juan","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2015.08.011_bib1020","doi-asserted-by":"crossref","first-page":"2390","DOI":"10.1128\/AAC.01737-10","article-title":"Antimicrobial activity of CXA-101, a novel cephalosporin tested in combination with tazobactam against Enterobacteriaceae, Pseudomonas aeruginosa, and Bacteroides fragilis strains having various resistance phenotypes","volume":"55","author":"Sader","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2015.08.011_bib1025","doi-asserted-by":"crossref","first-page":"6305","DOI":"10.1128\/AAC.01802-13","article-title":"Antimicrobial activity of ceftolozane\u2013tazobactam tested against Enterobacteriaceae and Pseudomonas aeruginosa with various resistance patterns isolated in U.S. hospitals (2011\u20132012)","volume":"57","author":"Farrell","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2015.08.011_bib1030","doi-asserted-by":"crossref","first-page":"1564","DOI":"10.1016\/j.clinthera.2015.05.501","article-title":"Susceptibility profile of ceftolozane\/tazobactam and other parenteral antimicrobials against Escherichia coli. Klebsiella pneumoniae, and Pseudomonas aeruginosa from US hospitals","volume":"37","author":"Sutherland","year":"2015","journal-title":"Clin Ther"},{"key":"10.1016\/j.ijantimicag.2015.08.011_bib1035","doi-asserted-by":"crossref","first-page":"2713","DOI":"10.1093\/jac\/dku184","article-title":"Antimicrobial activity of ceftolozane\/tazobactam tested against Pseudomonas aeruginosa and Enterobacteriaceae with various resistance patterns isolated in European hospitals (2011\u201312)","volume":"69","author":"Sader","year":"2014","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2015.08.011_bib1040","doi-asserted-by":"crossref","first-page":"4049","DOI":"10.1128\/JCM.02357-14","article-title":"In vitro activity of ceftolozane\u2013tazobactam as determined by broth dilution and agar diffusion assays against recent U.S. Escherichia coli isolates from 2010 to 2011 carrying CTX-M-type extended-spectrum \u03b2-lactamases","volume":"52","author":"Estabrook","year":"2014","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.ijantimicag.2015.08.011_bib1045","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1128\/AAC.01590-12","article-title":"In vivo activities of ceftolozane, a new cephalosporin, with and without tazobactam against Pseudomonas aeruginosa and Enterobacteriaceae, including strains with extended-spectrum \u03b2-lactamases, in the thighs of neutropenic mice","volume":"57","author":"Craig","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2015.08.011_bib1050","doi-asserted-by":"crossref","first-page":"2809","DOI":"10.1128\/AAC.02513-12","article-title":"Pharmacokinetics\u2013pharmacodynamics of tazobactam in combination with ceftolozane in an in vitro infection model","volume":"57","author":"VanScoy","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2015.08.011_bib1055","doi-asserted-by":"crossref","first-page":"3373","DOI":"10.1128\/AAC.04402-14","article-title":"Plasma and epithelial lining fluid pharmacokinetics of ceftolozane and tazobactam alone and in combination in mice","volume":"59","author":"Melchers","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2015.08.011_bib1060","series-title":"Highlights of prescribing information for Zerbaxa\u2122","author":"US Food and Drug Administration","year":"2015"},{"key":"10.1016\/j.ijantimicag.2015.08.011_bib1065","doi-asserted-by":"crossref","first-page":"1462","DOI":"10.1093\/cid\/civ097","article-title":"Ceftolozane\/tazobactam plus metronidazole for complicated intra-abdominal infections in an era of multidrug resistance: results from a randomized, double-blind, phase 3 trial (ASPECT-cIAI)","volume":"60","author":"Solomkin","year":"2015","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2015.08.011_bib1070","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.1016\/S0140-6736(14)62220-0","article-title":"Ceftolozane\u2013tazobactam compared with levofloxacin in the treatment of complicated urinary-tract infections, including pyelonephritis: a randomised, double-blind, phase 3 trial (ASPECT-cUTI)","volume":"385","author":"Wagenlehner","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.ijantimicag.2015.08.011_bib1075","doi-asserted-by":"crossref","first-page":"2463","DOI":"10.1093\/jac\/dks246","article-title":"Intrapulmonary penetration of ceftolozane\/tazobactam and piperacillin\/tazobactam in healthy adult subjects","volume":"67","author":"Chandorkar","year":"2012","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2015.08.011_bib1080","unstructured":"US National Institutes of Health. ClinicalTrials.gov. http:\/\/clinicaltrials.gov\/ct2\/home [accessed 15.08.15]."},{"key":"10.1016\/j.ijantimicag.2015.08.011_bib1085","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00825-15","article-title":"Mutations in \u03b2-lactamase AmpC increase resistance of Pseudomonas aeruginosa isolates to antipseudomonal cephalosporins","author":"Berrazeg","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2015.08.011_bib1090","doi-asserted-by":"crossref","first-page":"6844","DOI":"10.1128\/AAC.03681-14","article-title":"Mutation-driven \u03b2-lactam resistance mechanisms among contemporary ceftazidime-nonsusceptible Pseudomonas aeruginosa isolates from U.S. hospitals","volume":"58","author":"Castanheira","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2015.08.011_bib1095","doi-asserted-by":"crossref","first-page":"3091","DOI":"10.1128\/AAC.02462-13","article-title":"Pseudomonas aeruginosa ceftolozane\u2013tazobactam resistance development requires multiple mutations leading to overexpression and structural modification of AmpC","volume":"58","author":"Cabot","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2015.08.011_bib1100","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1007\/s40265-013-0013-7","article-title":"Ceftazidime\u2013avibactam: a novel cephalosporin\/\u03b2-lactamase inhibitor combination","volume":"73","author":"Zhanel","year":"2013","journal-title":"Drugs"},{"key":"10.1016\/j.ijantimicag.2015.08.011_bib1105","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.1128\/AAC.04191-14","article-title":"In vitro susceptibility of characterized \u03b2-lactamase-producing strains tested with avibactam combinations","volume":"59","author":"Li","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2015.08.011_bib1110","doi-asserted-by":"crossref","first-page":"1931","DOI":"10.1128\/AAC.04218-14","article-title":"In vitro antibacterial activity of the ceftazidime\u2013avibactam combination against Enterobacteriaceae, including strains with well characterized \u03b2-lactamases","volume":"59","author":"Levasseur","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2015.08.011_bib1115","doi-asserted-by":"crossref","first-page":"3509","DOI":"10.1128\/AAC.00163-15","article-title":"Ceftazidime\u2013avibactam activity tested against Enterobacteriaceae isolates from U.S. hospitals (2011 to 2013) and characterization of \u03b2-lactamase-producing strains","volume":"59","author":"Castanheira","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2015.08.011_bib1120","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1128\/AAC.04146-14","article-title":"In vitro activity of ceftazidime\u2013avibactam combination in in vitro checkerboard assays","volume":"59","author":"Berkhout","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2015.08.011_bib1125","doi-asserted-by":"crossref","first-page":"1774","DOI":"10.1128\/AAC.02123-13","article-title":"In vitro activities of ceftazidime\u2013avibactam and aztreonam\u2013avibactam against 372 Gram-negative bacilli collected in 2011 and 2012 from 11 teaching hospitals in China","volume":"58","author":"Wang","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2015.08.011_bib1130","doi-asserted-by":"crossref","first-page":"1684","DOI":"10.1128\/AAC.02429-13","article-title":"Antimicrobial activity of ceftazidime\u2013avibactam against Gram-negative organisms collected from U.S. medical centers in 2012","volume":"58","author":"Sader","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2015.08.011_bib1135","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/j.diagmicrobio.2014.07.005","article-title":"Ceftazidime\u2013avibactam and comparator agents tested against urinary tract isolates from a global surveillance program (2011)","volume":"80","author":"Flamm","year":"2014","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1016\/j.ijantimicag.2015.08.011_bib1140","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1093\/jac\/dku025","article-title":"Ceftazidime\/avibactam activity tested against Gram-negative bacteria isolated from bloodstream, pneumonia, intra-abdominal and urinary tract infections in US medical centres (2012)","volume":"69","author":"Flamm","year":"2014","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2015.08.011_bib1145","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.ijantimicag.2015.02.022","article-title":"Ceftazidime\/avibactam tested against Gram-negative bacteria from intensive care unit (ICU) and non-ICU patients, including those with ventilator-associated pneumonia","volume":"46","author":"Sader","year":"2015","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.ijantimicag.2015.08.011_bib1150","doi-asserted-by":"crossref","first-page":"3656","DOI":"10.1128\/AAC.05024-14","article-title":"Ceftazidime\u2013avibactam activity against multidrug-resistant Pseudomonas aeruginosa isolated in U.S. medical centers in 2012 and 2013","volume":"59","author":"Sader","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2015.08.011_bib1155","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1016\/j.ijantimicag.2014.12.033","article-title":"In vitro activity of ceftazidime, ceftaroline and aztreonam alone and in combination with avibactam against European Gram-negative and Gram-positive clinical isolates","volume":"45","author":"Testa","year":"2015","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.ijantimicag.2015.08.011_bib1160","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1179\/1973947813Y.0000000145","article-title":"Avibactam reverts the ceftazidime MIC90 of European Gram-negative bacterial clinical isolates to the epidemiological cut-off value","volume":"26","author":"Flamm","year":"2014","journal-title":"J Chemother"},{"key":"10.1016\/j.ijantimicag.2015.08.011_bib1165","doi-asserted-by":"crossref","first-page":"5793","DOI":"10.1128\/AAC.00548-15","article-title":"Effects of Klebsiella pneumoniae carbapenemase subtypes, extended-spectrum \u03b2-lactamases, and porin mutations on the in vitro activity of ceftazidime\u2013avibactam against carbapenem-resistant K. pneumoniae","volume":"59","author":"Shields","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2015.08.011_bib1170","doi-asserted-by":"crossref","first-page":"3710","DOI":"10.1128\/AAC.04406-14","article-title":"Variants of \u03b2-lactamase KPC-2 that are resistant to inhibition by avibactam","volume":"59","author":"Papp-Wallace","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2015.08.011_bib1175","doi-asserted-by":"crossref","first-page":"3700","DOI":"10.1128\/AAC.04405-14","article-title":"Avibactam and inhibitor-resistant SHV \u03b2-lactamases","volume":"59","author":"Winkler","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2015.08.011_bib1180","doi-asserted-by":"crossref","first-page":"1650","DOI":"10.1093\/jac\/dkv004","article-title":"Selection and molecular characterization of ceftazidime\/avibactam-resistant mutants in Pseudomonas aeruginosa strains containing derepressed AmpC","volume":"70","author":"Lahiri","year":"2015","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2015.08.011_bib1185","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1128\/AAC.04238-14","article-title":"Unexpected challenges in treating multidrug-resistant Gram-negative bacteria: resistance to ceftazidime\u2013avibactam in archived isolates of Pseudomonas aeruginosa","volume":"59","author":"Winkler","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2015.08.011_bib1190","doi-asserted-by":"crossref","first-page":"5324","DOI":"10.1128\/AAC.00678-15","article-title":"In vitro selection of ceftazidime\u2013avibactam resistance in Enterobacteriaceae with KPC-3 carbapenemase","volume":"59","author":"Livermore","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2015.08.011_bib1195","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01165-15","article-title":"First report of ceftazidime\u2013avibactam resistance in a KPC-3 expressing Klebsiella pneumoniae","author":"Humphries","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2015.08.011_bib1200","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1139\/cjm-2013-0089","article-title":"Is the GAIN Act a turning point in new antibiotic discovery?","volume":"59","author":"Brown","year":"2013","journal-title":"Can J Microbiol"},{"key":"10.1016\/j.ijantimicag.2015.08.011_bib1205","series-title":"FDA approves new antibacterial drug Avycaz","author":"US Food and Drug Administration","year":"2015"},{"key":"10.1016\/j.ijantimicag.2015.08.011_bib1210","doi-asserted-by":"crossref","first-page":"491","DOI":"10.2146\/ajhp100181","article-title":"Ceftaroline: a new broad-spectrum cephalosporin","volume":"68","author":"Lim","year":"2011","journal-title":"Am J Health Syst Pharm"},{"key":"10.1016\/j.ijantimicag.2015.08.011_bib1215","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1128\/AAC.00019-10","article-title":"Affinity of ceftaroline and other \u03b2-lactams for penicillin-binding proteins from Staphylococcus aureus and Streptococcus pneumoniae","volume":"54","author":"Kosowska-Shick","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2015.08.011_bib1220","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1007\/s10156-004-0309-3","article-title":"In vitro antimicrobial activity of T-91825, a novel anti-MRSA cephalosporin, and in vivo anti-MRSA activity of its prodrug, TAK-599","volume":"10","author":"Iizawa","year":"2004","journal-title":"J Infect Chemother"},{"key":"10.1016\/j.ijantimicag.2015.08.011_bib1225","doi-asserted-by":"crossref","first-page":"2053","DOI":"10.1093\/jac\/dkv076","article-title":"Activity of ceftaroline and comparator agents tested against Staphylococcus aureus from patients with bloodstream infections in US medical centres (2009\u201313)","volume":"70","author":"Sader","year":"2015","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2015.08.011_bib1230","doi-asserted-by":"crossref","first-page":"177","DOI":"10.47102\/annals-acadmedsg.V43N3p177","article-title":"Ceftaroline\u2014an anti-MRSA cephalosporin and its implications for Singapore","volume":"43","author":"Chen","year":"2014","journal-title":"Ann Acad Med Singapore"},{"key":"10.1016\/j.ijantimicag.2015.08.011_bib1235","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.diagmicrobio.2015.02.003","article-title":"Activities of ceftazidime, ceftaroline, and aztreonam alone and combined with avibactam against isogenic Escherichia coli strains expressing selected single \u03b2-lactamases","volume":"82","author":"Papp-Wallace","year":"2015","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1016\/j.ijantimicag.2015.08.011_bib1240","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/j.diagmicrobio.2014.01.003","article-title":"Antimicrobial activity of ceftaroline combined with avibactam tested against bacterial organisms isolated from acute bacterial skin and skin structure infections in United States medical centers (2010\u20132012)","volume":"78","author":"Flamm","year":"2014","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1016\/j.ijantimicag.2015.08.011_bib1245","doi-asserted-by":"crossref","first-page":"4779","DOI":"10.1128\/AAC.00817-12","article-title":"Activity of ceftaroline\u2013avibactam tested against Gram-negative organism populations, including strains expressing one or more \u03b2-lactamases and methicillin-resistant Staphylococcus aureus carrying various staphylococcal cassette chromosome mec types","volume":"56","author":"Castanheira","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2015.08.011_bib1250","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.1128\/AAC.02134-12","article-title":"Single- and multiple-dose study to determine the safety, tolerability, and pharmacokinetics of ceftaroline fosamil in combination with avibactam in healthy subjects","volume":"57","author":"Riccobene","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2015.08.011_bib1255","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1016\/j.clinthera.2015.01.009","article-title":"Effect of age and sex on the pharmacokinetics and safety of avibactam in healthy volunteers","volume":"37","author":"Tarral","year":"2015","journal-title":"Clin Ther"},{"key":"10.1016\/j.ijantimicag.2015.08.011_bib1260","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1124\/dmd.113.055335","article-title":"Assessment of the mass balance recovery and metabolite profile of avibactam in humans and in vitro drug\u2013drug interaction potential","volume":"42","author":"Vishwanathan","year":"2014","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.ijantimicag.2015.08.011_bib1265","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1002\/jcph.199","article-title":"Randomized, placebo-controlled study to assess the impact on QT\/QTc interval of supratherapeutic doses of ceftazidime\u2013avibactam or ceftaroline fosamil\u2013avibactam","volume":"54","author":"Das","year":"2014","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.ijantimicag.2015.08.011_bib1270","doi-asserted-by":"crossref","first-page":"4504","DOI":"10.1128\/AAC.00530-15","article-title":"Ecological effect of ceftaroline\u2013avibactam on the normal human intestinal microbiota","volume":"59","author":"Rashid","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2015.08.011_bib1275","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1128\/AAC.44.4.891-897.2000","article-title":"Characterization of VIM-2, a carbapenem-hydrolyzing metallo-\u03b2-lactamase and its plasmid- and integron-borne gene from a Pseudomonas aeruginosa clinical isolate in France","volume":"44","author":"Poirel","year":"2000","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2015.08.011_bib1280","doi-asserted-by":"crossref","first-page":"5046","DOI":"10.1128\/AAC.00774-09","article-title":"Characterization of a new metallo-\u03b2-lactamase gene, blaNDM-1, and a novel erythromycin esterase gene carried on a unique genetic structure in Klebsiella pneumoniae sequence type 14 from India","volume":"53","author":"Yong","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2015.08.011_bib1285","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1128\/JCM.34.4.908-911.1996","article-title":"Detection of extended-spectrum \u03b2-lactamases in clinical isolates of Klebsiella pneumoniae and Escherichia coli","volume":"34","author":"Jacoby","year":"1996","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.ijantimicag.2015.08.011_bib1290","doi-asserted-by":"crossref","first-page":"3881","DOI":"10.1128\/AAC.47.12.3881-3889.2003","article-title":"Carbapenem-resistant strain of Klebsiella oxytoca harboring carbapenem-hydrolyzing \u03b2-lactamase KPC-2","volume":"47","author":"Yigit","year":"2003","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2015.08.011_bib1295","doi-asserted-by":"crossref","first-page":"4239","DOI":"10.1128\/AAC.00206-15","article-title":"In vitro activity of aztreonam\u2013avibactam against a global collection of Gram-negative pathogens from 2012 and 2013","volume":"59","author":"Biedenbach","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2015.08.011_bib1300","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1128\/AAC.00756-10","article-title":"Activities of NXL104 combinations with ceftazidime and aztreonam against carbapenemase-producing Enterobacteriaceae","volume":"55","author":"Livermore","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2015.08.011_bib1305","unstructured":"[9th] Call for Proposals 2013. Innovative Medicines Initiative. http:\/\/www.imi.europa.eu\/sites\/default\/files\/uploads\/documents\/9th_Call\/Calll_9_Text.pdf [accessed 15.09.15]."},{"key":"10.1016\/j.ijantimicag.2015.08.011_bib1310","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1038\/nrmicro3245","article-title":"ND4BB: addressing the antimicrobial resistance crisis","volume":"12","author":"Rex","year":"2014","journal-title":"Nat Rev Microbiol"},{"key":"10.1016\/j.ijantimicag.2015.08.011_bib1315","series-title":"COMBACTE-CARE: a new public\u2013private funded project to combat carbapenem resistance","year":"2015"},{"key":"10.1016\/j.ijantimicag.2015.08.011_bib1320","doi-asserted-by":"crossref","first-page":"6137","DOI":"10.1128\/AAC.00851-12","article-title":"Comparative in vitro and in vivo efficacies of human simulated doses of ceftazidime and ceftazidime\u2013avibactam against Pseudomonas aeruginosa","volume":"56","author":"Crandon","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2015.08.011_bib1325","doi-asserted-by":"crossref","first-page":"3366","DOI":"10.1128\/AAC.00080-14","article-title":"Activities of ceftazidime and avibactam against \u03b2-lactamase-producing Enterobacteriaceae in a hollow-fiber pharmacodynamic model","volume":"58","author":"Coleman","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2015.08.011_bib1330","doi-asserted-by":"crossref","first-page":"2618","DOI":"10.1093\/jac\/dkv132","article-title":"Pharmacokinetics\/pharmacodynamics of a \u03b2-lactam and \u03b2-lactamase inhibitor combination: a novel approach for aztreonam\/avibactam","volume":"70","author":"Singh","year":"2015","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2015.08.011_bib1335","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1128\/AAC.02161-13","article-title":"Efficacies of ceftazidime\u2013avibactam and ceftazidime against Pseudomonas aeruginosa in a murine lung infection model","volume":"58","author":"Housman","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2015.08.011_bib1340","doi-asserted-by":"crossref","first-page":"2299","DOI":"10.1128\/AAC.04627-14","article-title":"Pharmacokinetics and penetration of ceftazidime and avibactam into epithelial lining fluid (ELF) in thigh- and lung-infected mice","volume":"59","author":"Berkhout","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2015.08.011_bib1345","first-page":"2286","article-title":"Activity of MK-7655 combined with imipenem against Enterobacteriaceae and Pseudomonas aeruginosa","volume":"68","author":"Livermore","year":"2013","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2015.08.011_bib1350","doi-asserted-by":"crossref","first-page":"5029","DOI":"10.1128\/AAC.00830-15","article-title":"Activity of imipenem with relebactam against Gram-negative pathogens from New York City","volume":"59","author":"Lapuebla","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2015.08.011_bib1355","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1086\/516284","article-title":"Pharmacokinetic\/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men","volume":"26","author":"Craig","year":"1998","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2015.08.011_bib1360","doi-asserted-by":"crossref","first-page":"2237","DOI":"10.1128\/AAC.06113-11","article-title":"A novel modeling framework to guide design of optimal dosing strategies for \u03b2-lactamase inhibitors","volume":"56","author":"Bhagunde","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2015.08.011_bib1365","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1128\/AAC.03706-14","article-title":"Pharmacodynamics of imipenem in combination with \u03b2-lactamase inhibitor MK7655 in a murine thigh model","volume":"59","author":"Mavridou","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2015.08.011_bib1370","doi-asserted-by":"crossref","first-page":"1825","DOI":"10.1093\/jac\/dkt118","article-title":"Activity of biapenem (RPX2003) combined with the boronate \u03b2-lactamase inhibitor RPX7009 against carbapenem-resistant Enterobacteriaceae","volume":"68","author":"Livermore","year":"2013","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2015.08.011_bib1375","doi-asserted-by":"crossref","first-page":"2620","DOI":"10.1128\/AAC.02418-12","article-title":"In vitro activity of biapenem plus RPX7009, a carbapenem combined with a serine \u03b2-lactamase inhibitor, against anaerobic bacteria","volume":"57","author":"Goldstein","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2015.08.011_bib1380","doi-asserted-by":"crossref","first-page":"4856","DOI":"10.1128\/AAC.00843-15","article-title":"Activity of meropenem combined with RPX7009, a novel \u03b2-lactamase inhibitor, against Gram-negative clinical isolates in New York City","volume":"59","author":"Lapuebla","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2015.08.011_bib1385","series-title":"54th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC)","article-title":"Comparative potency of cefepime (FEP) and cefepime\/AAI101 (FEP\/AAI101) against highly resistant Enterobacteriaceae","author":"Crandon","year":"2014"},{"key":"10.1016\/j.ijantimicag.2015.08.011_bib1390","doi-asserted-by":"crossref","first-page":"2688","DOI":"10.1128\/AAC.00033-15","article-title":"In vivo activities of simulated human doses of cefepime and cefepime\u2013AAI101 against multidrug-resistant Gram-negative Enterobacteriaceae","volume":"59","author":"Crandon","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2015.08.011_bib1395","series-title":"24th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID)","article-title":"Characterization of \u03b2-lactamase inhibition by AAI101, an extended spectrum \u03b2-lactamase inhibitor","year":"2014"},{"key":"10.1016\/j.ijantimicag.2015.08.011_bib1400","series-title":"24th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID)","article-title":"In-vitro activity of diverse \u03b2-lactam\/AAI101 combinations vs. multidrug-resistant Gram-negative clinical strains","author":"Mushtaq","year":"2014"},{"key":"10.1016\/j.ijantimicag.2015.08.011_bib1405","first-page":"237","article-title":"AmpC \u03b2-lactamases in nosocomial isolates of Klebsiella pneumoniae from India","volume":"136","author":"Gupta","year":"2012","journal-title":"Indian J Med Res"},{"key":"10.1016\/j.ijantimicag.2015.08.011_bib1410","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1038\/ja.2014.45","article-title":"Antimicrobial activity of cefepime\u2013tazobactam combination tested against clinical isolates of Enterobacteriaceae","volume":"67","author":"Kaur","year":"2014","journal-title":"J Antibiot (Tokyo)"},{"key":"10.1016\/j.ijantimicag.2015.08.011_bib1415","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1017\/S0022215115001127","article-title":"Occurrence of otitis media in children and assessment of treatment options","volume":"129","author":"Nwokoye","year":"2015","journal-title":"J Laryngol Otol"},{"key":"10.1016\/j.ijantimicag.2015.08.011_bib1420","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1007\/5584_2015_124","article-title":"Implementation of hospital's antibiotic policy decreases antimicrobial use in the general pediatric ward","volume":"857","author":"Nitsch-Osuch","year":"2015","journal-title":"Adv Exp Med Biol"},{"key":"10.1016\/j.ijantimicag.2015.08.011_bib1425","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1177\/1060028015579427","article-title":"Clinical and economic impact of empirical extended-infusion piperacillin\u2013tazobactam in a community medical center","volume":"49","author":"Brunetti","year":"2015","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.ijantimicag.2015.08.011_bib1430","series-title":"Drugs@FDA. FDA approved drug products","author":"US Food and Drug Administration","year":"2013"}],"container-title":["International Journal of Antimicrobial Agents"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924857915003180?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924857915003180?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,8,14]],"date-time":"2023-08-14T15:48:31Z","timestamp":1692028111000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0924857915003180"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,11]]},"references-count":143,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2015,11]]}},"alternative-id":["S0924857915003180"],"URL":"https:\/\/doi.org\/10.1016\/j.ijantimicag.2015.08.011","relation":{},"ISSN":["0924-8579"],"issn-type":[{"value":"0924-8579","type":"print"}],"subject":[],"published":{"date-parts":[[2015,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A resurgence of \u03b2-lactamase inhibitor combinations effective against multidrug-resistant Gram-negative pathogens","name":"articletitle","label":"Article Title"},{"value":"International Journal of Antimicrobial Agents","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijantimicag.2015.08.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier B.V. and the International Society of Chemotherapy. All rights reserved.","name":"copyright","label":"Copyright"}]}}